Saniona reaches ”most important milestone since the beginning”
A Mexican partner of the Danish biotech company Saniona has been approved to undertake a phase III study of the candidate drug tesofensine for treating obesity. CEO Jørgen Drejer describes this as the “most important milestone” since the company's beginning in April 2012.
BY MARTIN HAVTORN PETERSEN
The Danish biotech company Saniona is getting one step closer to the beginning of a phase III study of their candidate drug tesofensine for treating obesity. Saniona’s Mexican partner, Medix, has received permission from the Mexican authorities to undertake the important study, informs Saniona in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Saniona share spikes on strong diabetes data
For abonnenter
Saniona expands partnership with Upsher-Smith subsidiary
For abonnenter
